Epigenomics AG: strategic in vitro diagnostics partnership with Abbott Molecular
Collaboration focuses on development and global commercialization of a molecular diagnostic test for the early detection of colorectal cancer.
Abbott obtains non-exclusive worldwide rights to Epigenomics' proprietary DNA methylation biomarker Septin 9
Anticipate European market launch in 2009; filing for U.S. approval in 2010
Epigenomics to receive an up-front fee, milestone payments and royalties
Option to expand partnership on multiple Epigenomics biomarkers to other cancer indications
Epigenomics AG has signed a non-exclusive strategic collaboration and license agreement in molecular diagnostics with Abbott, a global healthcare company. Under the agreement, Abbott and Epigenomics intend to develop an in vitro diagnostic blood test for the early detection of colorectal cancer based on Epigenomics' proprietary DNA methylation biomarker Septin 9.
The companies anticipate launching a CE-marked test in Europe in 2009 followed by regulatory filing for U.S. approval in 2010. Under the terms of the agreement, Epigenomics will receive an up-front fee, milestone payments and royalties on product sales.
The agreement also contains provisions for the evaluation by Abbott of some of Epigenomics' other proprietary biomarkers for additional cancer indications.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.